文献速递临床生化临床免疫质量管理与危急值

生物胺作为神经内分泌肿瘤标志物:局限性与未来展望

Biogenic amines as neuroendocrine tumor markers: limitations and future perspectives.
PubMed 文献 · Clin Chem Lab Med · 2026-10-19

本文综述生物胺及其代谢物在嗜铬细胞瘤、副神经节瘤和神经母细胞瘤等神经内分泌肿瘤中的生化标志物作用。液相色谱-串联质谱显著提升分析灵敏度和特异性,多通路检测可提高诊断敏感性。多巴胺代谢物3-甲氧酪胺与MYCN相关肿瘤生物学及不良预后相关,但质谱方法复杂且缺乏完整计量溯源性,限制实验室间可比性。

要点

  • 生物胺标志物存在显著生理变异、分析前影响和方法学异质性。
  • 液相色谱-串联质谱提升分析性能,多通路检测提高诊断敏感性。
  • 3-甲氧酪胺与MYCN相关肿瘤生物学及不良临床结局相关。

核心结论

  • 生物胺及其代谢物是儿茶酚胺产生性神经内分泌肿瘤的核心生化标志物。
  • 质谱技术进步提升了分析性能,但方法复杂性和缺乏计量溯源性仍限制实验室间可比性。

研究设计与样本

  • 本文为综述,评估生物胺检测的分析演变、分析前和方法学决定因素及 harmonization 努力。

主要发现

  • 从比色法和免疫分析向液相色谱-串联质谱过渡显著提高了分析灵敏度和特异性。
  • 现代质谱平台的多通路能力可全面定量生物胺谱,提高单个标志物性能有限肿瘤亚型的诊断敏感性。
  • 3-甲氧酪胺与神经母细胞瘤和部分副神经节瘤亚型的MYCN相关肿瘤生物学及不良临床结局相关。

关键数值与推荐

  • 原文未报告具体数值标准。

临床怎么用

  • 关注3-甲氧酪胺等多巴胺代谢物的预后价值。
  • 推动扩展生物胺谱整合入临床稳健且可比的诊断方法以推进精准肿瘤学。

局限性

  • 质谱方法分析复杂且缺乏完整计量溯源性,限制实验室间可比性。
  • 生物胺标志物存在显著生理变异和分析前影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Biogenic amines and their metabolites are central biochemical markers in the diagnosis and management of catecholamine-producing neuroendocrine tumors, including pheochromocytoma, paraganglioma, and neuroblastoma. Despite decades of clinical use, their wider implementation remains limited by substantial physiological variability, pre-analytical influences, and methodological heterogeneity across laboratories. The transition from colorimetric and immunoassay-based techniques to liquid chromatography-tandem mass spectrometry has markedly improved analytical sensitivity and specificity. The multiplexing capacity of modern mass spectrometric platforms has enabled comprehensive quantification of biogenic amine profiles, thereby increasing diagnostic sensitivity in tumor subtypes in which individual biomarkers exhibit limited performance. Increasing attention has been given to dopamine derived metabolites, especially 3-methoxytyramine, which is associated with MYCN-related tumor biology and unfavorable clinical outcomes in neuroblastoma and selected paraganglioma subtypes. However, the analytical complexity of mass spectrometric approaches, together with the absence of full metrological traceability, continues to limit inter-laboratory comparability. In this review, we critically evaluate the analytical evolution of biogenic amine testing, the principal pre-analytical and methodological determinants that influence the interpretation of results, and current efforts to improve harmonization. Particular emphasis is placed on the potential of biogenic amines as prognostic biomarkers and on the need to integrate expanded biogenic amine profiling into clinically robust, comparable diagnostic approaches that may advance precision oncology.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Mellova M, Vicha A, Prusa R, et al. Biogenic amines as neuroendocrine tumor markers: limitations and future perspectives. Clin Chem Lab Med. 2026. PMID: 42886353. doi:10.1515/cclm-2026-0955

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。